Pharmazz, Inc. is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010, PMZ-1620 and PMZ-2123 for which it holds global marketing rights.
The indications for PMZ-2010, a small molecule, are hypovolemic shock and post-operative pain. The indications for PMZ-1620, a synthetic peptide, are neurovascular disorders and diagnostic use in differentiating solid tumors from benign to malignant. PMZ-1620 produces new blood vessels and neurons in the damaged brain. The indication for PMZ-2123, a synthetic peptide, is to treat cerebral edema in patients with diabetic ketoacidosis.